A novel tyrosine kinase inhibitor coated flow diverting stent as a drug delivery system for intracranial aneurysms

The purpose of the project is to develop a novel coating for a device that addresses both the pathogenesis of aneurysm formation as well as aneurysm occlusion. Prior studies on human tissue show that somatic variants within platelet derived growth factor beta (PDGFRB) are associated with the development of fusiform aneurysms within multiple vascular beds. Here, our central hypothesis is that a crystalline coating of small molecules of tyrosine kinase inhibitors (TKIs) on the surface of a flow diverting stent (FDS) will allow the formation of a stable carrier-free drug delivery system for sustained and localized delivery to the aneurysm. To test this hypothesis, I propose two aims. First, a crystalline coating of TKI will be synthesized on the surface of FDSs. This surface coating will be validated using microscopy and spectroscopy. Second, in vitro drug release from the surface of the device will be measured in both a static model and a 3D-printed aneurysm flow model.